AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr.

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras The ARVO Basis for Eye Analysis and Pfizer Ophthalmics are pleased to announce a series of awards named in honor of Carl B. Camras, MD. Up to three awards of $10,000 each will be presented each year for an interval of 10 years to early career experts. The AFER/Pfizer Ophthalmics/Carl Camras Translational Study Awards celebrate the entire existence and achievements of Dr. Camras, who passed away earlier this full season. Dr Camras was a glaucoma professional and analysis scientist who was most more popular for developing prostaglandin analogues for the treatment of elevated IOP in patients with glaucoma.Statistical Analysis The mutual exclusivity of pairs of mutations was evaluated by using two-by-two contingency tables and Fisher’s exact test. The association between mutations and cytogenetic risk classification was tested by using the chi-square test. Survival time was measured from the day of randomization to the day of death for sufferers who died and to the date of the last follow-up for individuals who were alive at the time of the evaluation. Multivariate analyses were carried out by using the Cox model with forward selection. We checked the proportional-hazards assumption by tests for a nonzero slope in a regression of the scaled Schoenfeld residuals on features of time .